Smith & Nephew SNATS (NYSE:SNN) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN) from a buy rating to a strong-buy rating in a report issued on Saturday.

SNN has been the subject of a number of other reports. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday. Finally, Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Stock Down 1.6%

SNN stock opened at $34.29 on Friday. The firm’s fifty day simple moving average is $34.43 and its 200-day simple moving average is $34.92. The company has a quick ratio of 1.40, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 12 month low of $23.91 and a 12 month high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be paid a $0.482 dividend. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.

Institutional Trading of Smith & Nephew SNATS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. River Road Asset Management LLC increased its holdings in Smith & Nephew SNATS by 9.3% in the second quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock valued at $97,175,000 after buying an additional 270,480 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Smith & Nephew SNATS by 5.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after acquiring an additional 100,697 shares in the last quarter. Brandes Investment Partners LP grew its position in shares of Smith & Nephew SNATS by 4.1% during the 2nd quarter. Brandes Investment Partners LP now owns 1,604,400 shares of the medical equipment provider’s stock valued at $49,143,000 after acquiring an additional 63,778 shares during the period. JPMorgan Chase & Co. grew its position in shares of Smith & Nephew SNATS by 6,663.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock valued at $37,082,000 after acquiring an additional 1,192,755 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock valued at $35,828,000 after purchasing an additional 575,666 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.